IQVIA (NYSE:IQV) Stock Rating Upgraded by Barclays

IQVIA (NYSE:IQV) was upgraded by research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a report issued on Friday, MarketBeat Ratings reports. The firm currently has a $210.00 target price on the medical research company’s stock. Barclays‘s price target suggests a potential upside of 20.30% from the stock’s current price.

Other equities research analysts have also issued reports about the company. BMO Capital Markets set a $250.00 price objective on IQVIA in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Jefferies Financial Group reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Finally, TD Cowen lifted their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Stock Down 2.2%

IQV opened at $174.56 on Friday. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a market capitalization of $29.62 billion, a P/E ratio of 22.21, a P/E/G ratio of 1.68 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm’s fifty day moving average price is $207.22 and its two-hundred day moving average price is $207.47.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boston Partners bought a new position in shares of IQVIA in the third quarter worth about $676,698,000. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA during the second quarter valued at approximately $515,772,000. Norges Bank acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $497,445,000. Victory Capital Management Inc. raised its position in IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Finally, Orbis Allan Gray Ltd lifted its holdings in IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after buying an additional 933,554 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.